

**UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

[Handwritten signature]

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. |
|-----------------|-------------|----------------------|---------------------|
|-----------------|-------------|----------------------|---------------------|

09/508,054 04/20/00 NG

F 017227/0156

HM22/0917

EXAMINER

FOLEY & LARDNER
3000 K STREET NW
SUITE 500 PO BOX 25696
WASHINGTON DC 20007-8696

SAQID, C

| ART UNIT | PAPER NUMBER |
|----------|--------------|
|----------|--------------|

1647

10

DATE MAILED:

09/17/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

| | |
|-------------------------------|---------------------------|
| Application No. 09/508,054 | Applicant(s) NG et al. |
| Examiner Christine Saoud | Art Unit 1647 |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on _____.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1, 7-18, 34, and 36-38 is/are pending in the application.

4a) Of the above, claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) _____ is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claims 1, 7-18, 34, and 36-38 are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are objected to by the Examiner.

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

a) All b) Some* c) None of:

- Certified copies of the priority documents have been received.
- Certified copies of the priority documents have been received in Application No. _____.
- Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). _____

16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152)

17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 20) Other: _____

Art Unit: 1647

DETAILED ACTION**Preliminary Amendment Non-entry**

Applicant filed a preliminary amendment on 07 March 2000. However, there are several errors in the directions for the amendment entry which have prohibited correct entry of the amendment. For example, the page numbers and line numbers do not correspond with the 2nd, 3rd, 4th and 5th entries. One of the directions recites "beginning on page 26 at lines 21 and 29 16 with the following". The first reference to page 26 is incorrect, and it is not clear what is meant by "29 16". It is suggested that the preliminary amendment be resubmitted, with careful attention being directed to page and line numbers, as well as clear directions for entry.

Additionally, the format of the amended claims is confusing in that it is not clear what elements are to be included in claim 16. There is no punctuation between the members of the markush group, the use of columns (ref. No. and Structure) is not proper, the run on of the sequences to multiple lines overlaps with the columns, the underlining of amino acids is confusing as there is no definition for the significance, etc. It is recommended that the claim be redrafted in such a way that the members of the Markush group are clear, with proper punctuation, wherein columns and headings are not used, but such that this information is conveyed in words, with proper explanation for the use of underlining or elimination of such, with the elimination of redundant information (peptide nomenclature). Correction is necessary for examination of the instant application.

Art Unit: 1647

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in response to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 7-16, 36-37, drawn to peptides.

Group II, claim(s) 17-18, 34, 38, drawn to methods of treating.

2. The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of Group I, the polypeptides, was known in the art prior to the filing of the instant application (see search report, especially Ng et al.), therefore, it cannot serve as a special technical feature. The “special technical features” means those technical features that define a contribution over the prior art (see MPEP 1850). Thus, the apparent “special technical feature” of these claims cannot form a basis for Unity of invention. The special technical feature of Group II is the method of treatment. In addition, Applicant should note that each peptide encompassed in Group I and used in Group II lacks unity of invention because each peptide is a “special technical feature”. Applicant is required to elect a single peptide for examination, regardless of whether Group I or Group II is elected. This is an election of invention as each peptide lacks unity of invention with each other.

Art Unit: 1647

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christine Saoud, Ph.D., whose telephone number is (703) 305-7519. The examiner can normally be reached on Monday to Friday from 7AM to 3PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, can be reached on (703) 308-4623.

Certain papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1 (CM1). The faxing of such papers must conform with the notices published in the Official Gazette, 1156 OG 61 (November 16, 1993) and 1157 OG 94 (December 28, 1993) (see 37 C.F.R. § 1.6(d)). NOTE: If Applicant *does* submit a paper by fax, the original signed copy should be retained by Applicant or Applicant's representative. NO DUPLICATE COPIES SHOULD BE SUBMITTED so as to avoid the processing of duplicate papers.

Official papers filed by fax should be directed to (703) 308-4556. If this number is out of service, please call the Group receptionist for an alternate number. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294. Official papers should NOT be faxed to 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

September 14, 2001

**CHRISTINE J. SAoud
PRIMARY EXAMINER**

Christine J. Saoud